Appendix to Characterization of Small-Molecule Drug Substances in Type II DMFs Supporting ANDAs, Part I: Solution Nuclear Magnetic Resonance Spectroscopy
Huyi Zhang
Advertisement
Articles by Huyi Zhang
The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.
Advertisement
Latest Updated Articles
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug SubstancesPublished: March 15th 2016 | Updated:
- Appendix: Common Deficiencies Related to Solution NMR in the Type-II DMFs
Published: February 2nd 2017 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Leveraging AI/ML to Reduce Risk in Drug Development: Part One
2
New Targets for Clinical Trials in the European Union
3
Shifting from Trial-and-Error to Rational Design Drives Efficiency in Pharmaceutical Formulation
4
Nuclear Waste to Medicine: The UK’s Lead-212 Strategy for Cancer Care
5
